Assenagon Asset Management S.A. Adds $34M in DexCom, Inc. ($DXCM)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Assenagon Asset Management S.A. increased its position in DexCom, Inc. ($DXCM) by 40.18% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,719,249 shares of DexCom, Inc. after buying 492,800 shares during the quarter. Assenagon Asset Management S.A.'s holdings in DexCom, Inc. were worth $117.91 million as of its most recent filing.
DexCom, Inc. Stock Down 24.5%
Shares of DexCom, Inc. ($DXCM) traded around $68.58 on Saturday, down 24.5% for the day.
DexCom, Inc. Earnings
Analysts Set New Price Targets
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Get DexCom, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DXCM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.